371244-07-4

Basic information

• Product Name: 4(3H)-Quinazolinone, 2-(aMinoMethyl)-5-Methyl-3-(2-Methylphenyl)-
• Synonyms: 4(3H)-Quinazolinone, 2-(aMinoMethyl)-5-Methyl-3-(2-Methylphenyl)-;2-(aMinoMethyl)-5-Methyl-3-(2-Methylphenyl)-3,4- dihydroquinazolin-4-one
• CAS NO: 371244-07-4
• Molecular Formula: C₁₇H₁₇N₃O
• Molecular Weight: 279.33638
• Mol File: 371244-07-4.mol

Chemical Properties

• Boiling Point: 463.4±55.0 °C(Predicted)
• Appearance: /
• Density: 1.22±0.1 g/cm3(Predicted)
• PKA: 8.06±0.29(Predicted)
• CAS DataBase Reference: 4(3H)-Quinazolinone, 2-(aMinoMethyl)-5-Methyl-3-(2-Methylphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4(3H)-Quinazolinone, 2-(aMinoMethyl)-5-Methyl-3-(2-Methylphenyl)-(371244-07-4)
• EPA Substance Registry System: 4(3H)-Quinazolinone, 2-(aMinoMethyl)-5-Methyl-3-(2-Methylphenyl)-(371244-07-4)

Safety Data

• Hazardous Substances Data: 371244-07-4(Hazardous Substances Data)

Upstream product

• 371244-06-3 2-amino-6-methyl-N-o-tolylbenzamide 
• 371244-11-0 2-(chloromethyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one 
• 4389-50-8 2-amino-6-methylbenzoic acid 

Downstream Products

• 1365616-81-4 3-amino-N-{[5-methyl-3-(2-methylphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]methyl}pyrazine-2-carboxamide 

Relevant articles and documents

INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE

The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds

Inhibitors of human phosphatidylinositol 3-kinase delta

Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.